Evogene Ltd. — Form 6-K Summary
Business context and reporting period
Evogene Ltd. furnished this Form 6-K in September 2026. It identifies unaudited condensed consolidated financial statements and an Operating and Financial Review and Prospects for the six months ended June 30, 2026. The filing text provided here contains the cover and exhibit descriptions, not the exhibits themselves.
Financial results and material changes
The provided text does not state revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics, and does not describe changes versus the prior comparable period. It refers readers to Exhibits 99.1 and 99.2 for those details.
Guidance, risks, and unusual items
No guidance, outlook, management commentary, risks, contingencies, or unusual items are described in the provided text. The filing states that the exhibits are incorporated by reference into specified registration statements.
Key facts to verify
- Review Exhibit 99.1 for the interim financial statements, notes, and comparative-period figures.
- Review Exhibit 99.2 for management’s discussion of results, financial condition, outlook, and risks.
- Confirm the exhibits’ reported cash, debt, liquidity, and cash-flow information before drawing conclusions about the company’s financial position.